Johnson & Johnson (JNJ)
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage trial presented on Sunday.
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Johnson & Johnson (JNJ) reached $225.33 at the closing of the latest trading day, reflecting a -2.37% change compared to its last close.
Is Johnson & Johnson (JNJ) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Partnership strategy has produced great pharma bargains—and left the company exposed.
Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
What a $1 Million Dividend Portfolio Actually Pays After Federal AND State Taxes in California
A California retiree with a $1 million dividend portfolio earning a 5% blended yield grosses $50,000 in annual income.
Six Boring Blue Chips Generate $54,000 a Year on $920,000 Without a Single 7 Percent Yield Trap
The six names below sit firmly in the conservative-to-moderate tier. Five are Dividend Kings or Aristocrats.
Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $231.73, marking a +1.05% move from the previous day.
3 Dividend Aristocrats to Own For a Lifetime Of Passive Income
Paychecks stop. Bonuses get cut.
Johnson & Johnson (JNJ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Johnson & Johnson (JNJ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
J&J's Pipeline Progress & New Drugs Promise Stronger Long-Term Growth
J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.
